* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
Smurfit Westrock (SWR.L) has left the Main Market.
What’s baking in the oven?
Potential IPOs:***
3 June: Reveille Resources has announced its intention to IPO onto AQSE. The strategy is focused on identifying and advancing uranium exploration opportunities in assets that have benefited from significant historical expenditure and technical work, but which may not have achieved full value realisation due to geopolitical, technological, financial, or historical factors. Reveille’s initial focus is on two historical uranium deposits in Lombardy, northern Italy. Pre-admission, Andrea Cattaneo, Ippolito Cattaneo, Ajax Resources PLC, and Zenith Energy Ltd. each hold 25% of the shares. The four pre-admission shareholders will be subject to a one-year lock-in and a subsequent one-year orderly market agreement. Expected Admission date 25th June.
17 March: Vista Parcs Group has announced its intention to IPO onto AIM. The newly incorporated entity is proposing to acquire a portfolio of 13 UK-based holiday and residential parks currently owned by Barney Group 2 Ltd (BG2) and operated by Baslow Parks Ltd. Deal details TBC and expected Admission date anticipated late June 2026.
Reverse Transactions:***
19th December 2025: Talon Resources (TAR.L), previously Medcaw Investments, the Company focused on identifying and acquiring prospective mining projects in the precious metals sector, with a primary focus on gold and other high-value commodities announced that it has entered into binding heads of terms (which includes an exclusivity agreement until 31 October 2026) with Ulvestone Ltd in respect of the proposed acquisition by the Company of 90% of the legal and beneficial interest in certain mineral exploration licences located in Ontario, Canada. The aggregate consideration payable by Medcaw is £4.17m, to be satisfied £70k in cash on execution of the definitive share purchase agreement, £100k in cash on AIM Admission, and £4m satisfied through the issue of new ordinary shares in Medcaw at a price of 1.5p per share, to be issued on AIM Admission. The indicative timetable in relation to the Cancellation and proposed re-admission to trading on AIM has been revised and is now expected to take effect on 23 June.
Banquet Buffet****
London Stock Exchange: Main Market and AIM
80 Mile 0.92p £46.15m (80M.L)
The exploration and development Company with projects in Greenland, Finland and Italy, announced an update on recent developments at Disko-Nuussuaq nickel-copper-cobalt-PGE project in West Greenland, and the 2026 drill season. The Company will operate two diamond drill rigs at Disko for the 2026 season and further advise that in consultation with the joint venture partner, USFM Corporation who is spending US$30m for 51% over 3 years, that the 2026 drilling programme has been expanded from 5,000m to 9,000m.
CelLBxHealth 1.55p £19.94m (CLBX.L)
The CTC intelligence Company specialising in innovative circulating tumour cell (CTC) solutions announced its audited preliminary results for the year ending 31 December 2025. Total revenue was £1.4m (2024: £2.9m), gross profit margins held at 62% (2024: 62%) and there was a loss after tax of £19.5m (2024: £14.2m). Cash and cash equivalents was £7.3m at 31 December 2025 (2024: £10.4m). FY 2026 revenues are expected to be at least £2.1m based on contracted revenues and near-term commercial opportunities, representing anticipated growth of at least 50% over FY 2025. The Company has a cash runway into Q2 2027.
Conroy Gold and Natural Resources 10.0p £7.5m (CGNR.L)*
The gold exploration and development Company announced assay results from drillhole CGC-25-005 at Clontibret. Drillhole CGC-25-005 represents a step-out to the north on the Eastern Zone lodes and is interpreted to demonstrate increased confidence in the continuity between the Clontibret deposit and the Corcaskea area. Highlights include 4.8 metres at 1.3 g/t Au, including 0.9m @ 3.1 g/t Au and 1.0 metre at 2.7 g/t Au. Overall, the new data confirms the continuity of the Eastern Zone of the mineralised system northwards towards Corcaskea and provides additional support for the Company's interpretation of persistent gold-bearing lodes extending northwards.
eEnergy Group 3.20p £19.75m (EAAS.L)
The company which designs and delivers energy-saving and energy-generating solutions announced a trading update ahead of its AGM on 25th June. The Board now believes that investment grade opportunities equivalent to £66m more fairly reflect the level of live opportunities that the business could potentially convert into revenue in the short to medium term. The Board now expects H1-26 Revenue of circa £22.0m (H1-25: £10.1m) and H1-26 Adjusted EBITDA of circa £1.2m (H1-25: £0.5m). Following the detailed review and significant reduction in pipeline revenue, the Board now expects FY26 Revenue to be circa £32.0m (previously £38.0m FY25: £19.0m) with FY26 Adjusted EBITDA of £1.7m (previously £4.5m FY25: £2.2m).
Fusion Antibodies 12.50p £15.64m (FAB.L)
The contract research organisation announced that the Canadian Intellectual Property Office has issued a notice of allowance in respect of the Company's Canadian patent application no. 3,115,150. The Patent Application entitled "Antibody Library and Method", covers two families of antibodies, and the method for the design of such antibody libraries. The patent, once granted, is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation. The Company is also progressing additional patent applications in respect of the OptiMAL Library in Canada and several other territories worldwide including Europe and China.
Ondine Biomedical Inc 14.75p £81.38m (OBI.L)
The life sciences Company focused on the development of light-activated antimicrobial therapies announced an update on its LANTERN Phase 3 pivotal study evaluating the Company's non-antibiotic nasal photodisinfection technology. Endpoint adjudication has been completed, all queries resolved, and site principal investigators are signing all case books which is a required administrative step towards database lock. This is expected to complete within the coming week, and once complete, the locked dataset will be transferred to statistical analysis in accordance with the Statistical Analysis Plan. The Company expects to report top-line results within one to two weeks thereafter.
Proteome Sciences 1.51p £5.30m (PRM.L)
The specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification announced a further significant clinical contract connected to its target engagement chemoproteomics platform. The Company anticipates this contract being a precursor to a new clinical trial programme that will be initiated later in 2026.
Transense Technologies 47.50p £8.60m (TRT.L)
The provider of specialist sensing solutions and measurement systems provided an update on trading for the year ending 30 June 2026 (FY26) and outlook for FY27. The Company expects to report revenue of not less than £4.6m, adjusted EBITDA of not less than £0.5m and adjusted profit before tax of approximately break-even. This represents a modest reduction versus expectations set in January 2026. Cash at 31 May 2026 was £1.12m (31 December 2025: £1.33m) and net cash of £0.71m (31 December 2025: £0.92m). The Board remains confident in the Company's medium-term growth opportunities across both business segments.
Aquis Market:
Equipmake Holdings 1.25p £14.0m (AQSE:EQIP)
The industrial technology Company announced an update on trading for the year ended 31 May 2026 and announces changes to the Company's board of directors. In line with the expectations outlined in the Company's interim results, announced on 27 February 2026, trading in the second half of the financial year ended 31 May 2026 (FY26) has shown significant improvement over the first half, in particular reflecting revenue starting to be recognised from the approximately £8.8m of orders received from Agrale S.A. since September 2025. As a consequence, the Company expects, subject to audit, to report revenue (excluding grant income) in excess of £8m for FY26 (FY25 £3.5m, H1 FY26 £1.44m). The Company also announced the appointment of Jason Abbott, currently the Company's Operations Director, to the Board as Chief Operating Officer with immediate effect. Ian Selby, Chief Financial Officer, has informed the Board that he wishes to step down from his responsibilities at Equipmake to focus on his other business interests.
Sulnox Group 57.50p £83.12m (AQSE:SNOX)
The greentech Company delivering lower fuel costs and emissions announced the signing of a new four-year supply agreement with Eastern Pacific Shipping Pte Ltd (EPS), representing the largest commercial agreement in Sulnox's history. The agreement significantly expands deployment of Sulnox Eco across the EPS fleet, increasing usage from approximately 30 vessels to more than 50 vessels. The agreement covers the supply of approximately 1.2m litres of Sulnox Eco over the contract term and is accompanied by an increase in EPS's affiliate, EPS Ventures' (EPSV) strategic investment in Sulnox. The Board expects the agreement to generate significant revenue for Sulnox, further accelerating the Company's continued commercial growth.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
